Therapies with Emerging Evidence of Efficacy: Avotermin for the Improvement of Scarring

Table 2

Agents in development for the reduction of dermal scarring.

Agents in preclinical development for the reduction of dermal scarring
Company	Agent	Status
First String	polypeptide 𝛼-connexin	Preclinical
Phylogica	PYC-35B	Preclinical
Sirnaomics	STP-705	Preclinical
Agents in clinical development for the reduction of dermal scarring
Capstone Therapeutics	AZX-100: 24 amino acid peptide analogue of heat shock protein 20, an intracellular actin-relaxing molecule	Phase II
CoDa Therapeutics	Nexagon: an anti-connexin oligonucleotide, shown to increase rate of wound healing	Phase I
Excaliard	antisense inhibitors of Smads, Connective Tissue Growth Factor	Phase II
Renovo	Ilodecakin (Prevascar): recombinant human interleukin 10	Phase II
	Avotermin (Juvista): recombinant human TGF𝛽3	Phase III